Evidence map›Paper›PMID 38214877›Full record

ArticleEndocrine2024

Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemia.

Queralt Asla, Helena Sardà, Núria Seguí, Guillermo Martínez de Pinillos, Isabel Mazarico-Altisent, Ismael Capel, José Rives, Javier Suárez, Verónica Ávila-Rubio, Manuel Muñoz Torres and 9 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Queralt AslaDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-6049-8048
Helena SardàDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0002-0138-8217
Núria SeguíDepartment of Endocrinology and Nutrition, Hospital Clínic, Barcelona, Spain.
Guillermo Martínez de PinillosDepartment of Endocrinology, Hospital Universitario Virgen de Valme, Sevilla, Spain.
Isabel Mazarico-AltisentDepartment of Endocrinology and Nutrition, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.ORCID 0000-0001-9651-7650
Ismael CapelDepartment of Endocrinology and Nutrition, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.
José RivesDepartment of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Javier SuárezDepartment of Endocrinology and Nutrition, Hospital Arnau de Vilanova, Lleida, Spain.
Verónica Ávila-RubioDepartment of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain.
Manuel Muñoz TorresDepartment of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain.ORCID 0000-0002-9645-3260
Ignasi SaigíDepartment of Medicine, University of Vic-Central University of Catalonia, Vic, Spain.
Nuria PalaciosDepartment of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain.ORCID 0000-0001-7366-2476
Eulàlia UrgellDepartment of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Susan M WebbDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-7052-6436
Mercè FernándezDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau - Hospital Dos de Maig, Barcelona, Spain.
Josep OriolaDepartment of Biochemistry and Molecular Genetic, CDB, Hospital Clínic, Barcelona, Spain.
Mireia MoraDepartment of Endocrinology and Nutrition, Hospital Clínic, Barcelona, Spain.ORCID 0000-0002-5887-5016
Mireia TondoSant Pau Biomedical Research Institute (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0002-0301-9984
Anna AulinasDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. aaulinas@santpau.cat.ORCID 0000-0002-1205-7114
Hospital de Sant Pau · ESHospital Clínic de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ESInstitute of Research and Innovation Parc Tauli · ESUniversitat Autònoma de Barcelona · ESHospital Arnau de Vilanova · ESHospital Universitario de Valme · ESHospital Universitario Puerta de Hierro Majadahonda · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBiochemical suspicion of familial hypocalciuric hypercalcemia (FHH) might provide with a negative (FHH-negative) or positive (FHH-positive) genetic result. Understanding the differences between both groups may refine the identification of those with a positive genetic evaluation, aid management decisions and prospective surveillance. We aimed to compare FHH-positive and FHH-negative patients, and to identify predictive variables for FHH-positive cases.

designRetrospective, national multi-centre study of patients with suspected FHH and genetic testing of the CASR, AP2S1 and GNA11 genes.

methodsClinical, biochemical, radiological and treatment data were collected. We established a prediction model for the identification of FHH-positive cases by logistic regression analysis and area under the ROC curve (AUROC) was estimated.

resultsWe included 66 index cases, of which 30 (45.5%) had a pathogenic variant. FHH-positive cases were younger (p = 0.029), reported more frequently a positive family history (p < 0.001), presented higher magnesium (p < 0.001) and lower parathormone levels (p < 0.001) and were less often treated for hypercalcemia (p = 0.017) in comparison to FHH-negative cases. Magnesium levels showed the highest AUROC (0.825, 95%CI: 0.709-0.941). The multivariate analysis revealed that family history and magnesium levels were independent predictors of a positive genetic result. The predictive model showed an AUROC of 0.909 (95%CI: 0.826-0.991).

conclusionsThe combination of magnesium and a positive family history offered a good diagnostic accuracy to predict a positive genetic result. Therefore, the inclusion of magnesium measurement in the routine evaluation of patients with suspected FHH might provide insight into the identification of a positive genetic result of any of the CaSR-related genes.

Indexed as

HypercalcemiaHyperparathyroidism, PrimaryHumansMagnesiumProspective StudiesRetrospective StudiesMagnesiumcalcium disorderscalcium-sensing receptor (CaSR)CASR geneCASR mutationsFamilial hypocalciuric hypercalcemia (FHH)primary hyperparathyroidism (PHPT)

Identifiers

PMID38214877
PMCPMC10901938
OpenAlexW4390793982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.